NCT04842019View on ClinicalTrials.gov

Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 28, 2021

Primary Completion Date

August 17, 2023

Study Completion Date

August 17, 2023

Conditions

X-linked Hypophosphatemia (XLH)

Interventions

DRUG

KRN23

KRN23 is a sterile clear colourless and preservative free solution supplied in single use 5 mL vials containing 1 mL of KRN23 at a concentration of 30mg/mL

Trial Locations (5)

Unknown

Peking Union Medical College Hospital, Beijing

The First Medical Center of Chinese People's Liberation Army General Hospital, Beijing

Nanfang Hospital, Guangzhou

The Second Affiliated Hospital of Zhejiang University, Hangzhou

Shanghai 6th Hospital, Shanghai

All Listed Sponsors

lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT04842019 - Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH | Biotech Hunter | Biotech Hunter